Compare PCRX & TRUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | TRUP |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2010 | 2014 |
| Metric | PCRX | TRUP |
|---|---|---|
| Price | $36.35 | $27.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $33.57 | $33.25 |
| AVG Volume (30 Days) | ★ 2.1M | 353.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 107.44 | ★ 295.65 |
| EPS | 0.19 | ★ 0.27 |
| Revenue | $541,533,000.00 | ★ $1,439,305,000.00 |
| Revenue This Year | $3.84 | $10.58 |
| Revenue Next Year | $4.73 | $8.42 |
| P/E Ratio | $191.29 | ★ $104.07 |
| Revenue Growth | ★ 26.04 | 11.95 |
| 52 Week Low | $18.80 | $21.16 |
| 52 Week High | $36.67 | $46.98 |
| Indicator | PCRX | TRUP |
|---|---|---|
| Relative Strength Index (RSI) | 83.97 | 61.68 |
| Support Level | $21.78 | $24.15 |
| Resistance Level | N/A | $29.24 |
| Average True Range (ATR) | 0.40 | 0.92 |
| MACD | 0.89 | 0.52 |
| Stochastic Oscillator | 97.44 | 80.84 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions. Geographically, the company operates in United States, which derives maximum revenue; and Canada and Others.